Previous or concurrent active invasive cancers other than superficial non-melanoma skin cancers.Prior pelvic irradiation, (chemo)hormonal therapy or orchiectomy.Written (signed and dated) informed consent prior to registration.Age at inclusion between 18 and 80 years.WHO performance status 0-2 at inclusion.The first value must be measured at least 6 weeks after radical prostatectomy A recent PSMA-PET scan ( 0.1 ng/mL or 3 consecutive rises. Tumour stage pT2-4, R0-1, pN0, or cN0, cNx according to the UICC TNM 2009, only with Gleason score available.Patients with prostate adenocarcinoma treated with radical prostatectomy.Radiation: Conventional sEBRT Radiation: Hypofractionated sEBRT ![]() The primary endpoint will be the 5-year progression-free survival (PFS) after treatment. All patients with biochemical recurrence with a PSA 0.1 ng/mL or three consecutive rises will be included.Īll eligible patients will be randomized to one of the following two treatment arms:Īrm 1 = Conventional sEBRT to apply a total dose of 70 Gy in 35 daily fractions of 2 Gy during 7 weeks.Īrm 2 = Hypofractionated sEBRT to apply a total dose of 60 Gy in 20 fractions of 3 Gy during 4 weeks. The study is designed as a prospective open phase III randomized multicenter trial. The main goal of this project is to investigate whether the oncologic outcome in patients with post-prostatectomy recurrent PCa can be improved, by increasing the biological effective radiation dose using a hypofractionated schedule of 20 x 3 = 60 Gy. sEBRT can provide long-term disease control with 5 year biochemical progression-free survival (bPFS) up to 60% and with most treatment failures in the first 2 years after sEBRT. ![]() The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |